
Annual report 2023
added 02-29-2024
PetIQ Market Cap 2011-2025 | PETQ
As of December 15, 2025 PetIQ has a market cap of $ 400 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 396 M | 397 M | 641 M | 854 K | 696 M | 503 M | 323 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 696 M | 854 K | 422 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Canopy Growth Corporation
CGC
|
142 M | $ 1.68 | -3.44 % | $ 181 M | ||
|
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
66.1 M | $ 0.74 | -3.53 % | $ 52.6 M | ||
|
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
3.63 B | $ 3.05 | -6.88 % | $ 1.61 B | ||
|
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
915 M | $ 5.1 | -5.59 % | $ 86.3 M | ||
|
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | ||
|
Organogenesis Holdings
ORGO
|
415 M | $ 4.76 | -1.14 % | $ 627 M | ||
|
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M | ||
|
Pacira BioSciences
PCRX
|
1.18 B | $ 26.64 | 1.33 % | $ 1.23 B | ||
|
Emergent BioSolutions
EBS
|
139 M | $ 12.27 | 7.44 % | $ 628 M | ||
|
Evoke Pharma
EVOK
|
2.24 M | $ 10.97 | 0.14 % | $ 36.7 M | ||
|
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | ||
|
Rockwell Medical
RMTI
|
35.5 M | $ 0.88 | -5.2 % | $ 20.5 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
717 M | $ 21.43 | 0.3 % | $ 2.04 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 3.52 | -2.07 % | $ 4.37 M | ||
|
Evolus
EOLS
|
887 M | $ 7.14 | 1.42 % | $ 443 M | ||
|
Harrow Health
HROW
|
347 M | $ 46.39 | -1.43 % | $ 1.51 B | ||
|
China Pharma Holdings
CPHI
|
4.54 M | $ 1.53 | -1.92 % | $ 26.7 M | ||
|
Bausch Health Companies
BHC
|
3.38 B | $ 6.87 | -0.79 % | $ 2.51 B | ||
|
Veru
VERU
|
108 M | $ 2.39 | -1.24 % | $ 322 M | ||
|
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
382 M | $ 1.81 | -5.99 % | $ 402 M | ||
|
cbdMD
YCBD
|
1.68 M | $ 1.18 | -3.28 % | $ 5.09 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.04 | 20.16 % | $ 42.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | ||
|
Solid Biosciences
SLDB
|
226 M | $ 5.77 | -1.79 % | $ 236 M | ||
|
Relmada Therapeutics
RLMD
|
162 M | $ 4.34 | 6.9 % | $ 131 M | ||
|
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
3.96 B | $ 12.77 | -2.85 % | $ 1.75 B | ||
|
ProPhase Labs
PRPH
|
131 M | $ 0.12 | 0.87 % | $ 1.9 M | ||
|
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | ||
|
Sundial Growers
SNDL
|
889 K | $ 1.96 | -11.31 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
70.3 M | $ 0.64 | -0.91 % | $ 30.6 M | ||
|
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
1.19 B | $ 11.19 | -7.9 % | $ 6.92 B | ||
|
TherapeuticsMD
TXMD
|
23.9 M | $ 1.7 | -2.86 % | $ 17.7 M | ||
|
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
13.6 B | $ 11.65 | - | $ 14.1 B |